Literature DB >> 3033128

Suppression of delayed type hypersensitivity to herpes simplex virus type 1 following immunization with anti-idiotypic antibody: an example of split tolerance.

J L Lathey, S Martin, B T Rouse.   

Abstract

Intraperitoneal (i.p.) immunization with herpes simplex virus type 1 (HSV-1) or an anti-idiotypic antibody (anti-id C) prepared against a monoclonal antibody specific for glycoprotein C of HSV-1, tolerizes mice for an HSV-1 delayed type hypersensitivity (DTH) response. This tolerization could be adoptively transferred to naive X-irradiated mice by splenic T cells, and was specific for HSV-1 DTH. Thus, DTH-tolerized mice responded to vaccinia virus or HSV-2 challenge, while remaining tolerized for HSV-1 DTH. In addition, these animals demonstrated a form of split tolerance such that HSV antibody, cytotoxic T cell and lymphoproliferative responses were detected in vitro. Thus, anti-id C induced a T cell population capable of specifically suppressing the HSV-1 DTH response, mimicking the effect of i.p. and intravenous immunization with HSV-1 found previously.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3033128     DOI: 10.1099/0022-1317-68-4-1093

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  3 in total

1.  Herpes simplex virus-induced stromal keratitis: role of T-lymphocyte subsets in immunopathology.

Authors:  C K Newell; S Martin; D Sendele; C M Mercadal; B T Rouse
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

2.  Anti-idiotypic antibodies induce neutralizing antibodies to bovine herpesvirus 1.

Authors:  S Srikumaran; D V Onisk; M V Borca; C Nataraj; T J Zamb
Journal:  Immunology       Date:  1990-07       Impact factor: 7.397

3.  Induction of protective immunity and neutralizing antibodies to pseudorabies virus by immunization of anti-idiotypic antibodies.

Authors:  T Tsuda; T Onodera; T Sugimura; Y Murakami
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.